Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

pectations, and we are looking forward to taking the next steps toward bringing it to market for patients who need to improve their cholesterol levels. Our next step for the routine high cholesterol population is to conduct a longer-term Phase 2 study in patients in combination with statins, in which we expect to use induction doses of 200 to 300 mg/week and define maintenance doses in the range of 100 to 200 mg/week."

ISIS 301012 Coadministered with Statins

This randomized, double-blinded, placebo-controlled, dose-escalation study initially included five weeks of treatment at doses of 30, 100, 200, and 300 mg/week. Because ISIS 301012 was well tolerated in these cohorts, the study was expanded to include a 400 mg/week five-week treatment group and two longer-term treatment cohorts; results of dose cohorts through 300 mg/week were presented previously, results from the 400 mg/week cohort were presented today, and results from the longer-term cohorts will be presented later in the year. Patients in the five-week study had median baseline LDL-C levels between 107 and 168 mg/dL and had been on stable doses of < / = 40 mg of simvastatin or atorvastatin for at least three months, with a median statin treatment duration of 4 years. At a dose of 400 mg/week, patients receiving ISIS 301012 achieved median reductions of 51% in apoB, 47% in LDL-C, and 35% in TG beyond the levels they had already achieved on stable statin doses. ISIS 301012 treatment had no effect on HDL-cholesterol levels (HDL-C).

Interestingly, in this short-term study, increasing the dose from 300 mg/week to 400 mg/week did not result in further lipid lowering activity represented as median % changes from baselines. This apparent plateau in % reductions may be due to the higher baseline values in the 300 mg/week cohort relative to the 400 mg/week cohort. Indeed, the 400 mg/week cohort did achieve lower median absolute levels of both apoB (55 mg/dL at 400 mg/week versus 61 mg/dL at 300 m
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... 29, 2014 The clinical and medical insights ... difference between a product,s success or failure. Despite this, ... KOL targets – and then to coordinate activities and ... relationships upon which successful KOL engagement rests. ... identified internal inconsistencies in their KOL management systems and ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... , , Patient Advocacy Partners ... System , NEW YORK and MILAN, ... , the commercial drug development arm of the National Multiple Sclerosis ... the leader in research leading to a cure for type 1 diabetes ...
... , VENLO, The Netherlands ... than 90,000 Italian women published by the Lancet Oncology found ... significantly more effective in preventing invasive cervical cancer than cytology (Pap testing) ... as the digene® HC2 HPV DNA Test), which detects the ...
Cached Medicine Technology:Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 2Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 3Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 4Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 5Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 2Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 3Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 4Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 5Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 6
(Date:8/30/2014)... WA (PRWEB) August 30, 2014 “In 2013, ... alone,” The Jones Firm says in a recently released article ... “A person was injured in an auto accident every 12 ... 16 minutes,” they continue. “Based on the 2013 statistics, between ... a vehicle collision.” , The threat of an auto accident ...
(Date:8/30/2014)... 30, 2014 Final Cut Pro ... the TransGhost plugin from Pixel Film Studios. , “The ... the ability to tell their scary story in a ... Studios. “Users will make their audience scream with this ... With TransGhost users can awaken evil spirits with over ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 As 500 Zoloft ... defect when give to pregnant mothers, Wright & Schulte LLC ... Cynthia M. Rufe. The remand in the Zoloft ... of 18 states and are involved in one SSRI ... to have their Zoloft birth defect lawsuit sent back to ...
(Date:8/30/2014)... Zensah®, the leader in compression technology and comfort, has created ... sleeves are the first released as part of Zensah’s® DeZign ... classic colors like army green and bold new hues like ... syndrome, shin splints cause dull aches and pains in the ... stress fractures, or over pronation may also be one of ...
(Date:8/30/2014)... TN (PRWEB) August 30, 2014 The ... including nine mobilizations and six muscle energy techniques. Michael ... narrates and demonstrates twenty-seven examination techniques for the SI ... supports Dr. Reiman's live course presentation with North ... Applying a differential diagnosis approach ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 2Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2
... of developing eczema in babies is reduced by adding prebiotics ... gut bacteria //and fortifies the immune system. ... for Infant Nutrition revealed that topic dermatitis was ... than in those given the standard form. The results, published ...
... Association it was found that people were not interested to ... about health policy and speedy treatment. ,But in ... the public with a choice of hospitals. ... annual representative meeting in Belfast. The policy was prepared mostly ...
... Scientists have announced that they have discovered a new way ... a research that was published yesterday. // ,The ... make the brain repair itself after a stroke. In their ... suffering from an induced stroke, that after their treatment there ...
... Australian Therapeutic Goods Administration (TGA) has approved the cervical cancer ... ,Early June had seen the US Food and Drug ... in the United States for girls and women aged from ... by CSL. The vaccine was invented by University of Queensland ...
... New diagnosis method to monitor the production and clearance ... tracking human brain disorders. // ,Amyloid ... system of humans can now be possibly diagnosed with ... Washington University School of Medicine in St. Louis. ...
... African American women could be more prone to diabetes ... a protein hormone, present in fat cells. // ... results of their study that examined the relationships between ... ADIPO is known as a hormone that regulates the ...
Cached Medicine News:Health News:New Discovery Shows That Brain Could repair Itself After Stroke 2Health News:Abnormal Abeta - Protein Level in Human Brain Trigger Alzheimer's Risk 2Health News:Abnormal Abeta - Protein Level in Human Brain Trigger Alzheimer's Risk 3Health News:Fat Cell Hormone Could Trigger Diabetes, Heart Disease 2
... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
Inquire...
... The MicroCentrifuge Two Strip Rotor hold 16 ... mess with). Simply close the polycarbonate lid ... to open. Starts and stops in seconds. ... x g. Only five inches in diameter. ...
... Minifuge has an on/off switch which allows user ... improved safety. New hinge, with stainless steel pin ... work yet durable. Spins 6 microcentrifuge tubes at ... g). 6000rpm/2000 x g. 6 inch x 6 ...
Medicine Products: